Clinical Trial

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase II Study of CS0159 in Chinese patients with PSC(Primary Sclerosing Cholangitis)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-07; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2026-03-12
Status change: Not Yet Recruiting → Recruiting 2023-08-31
Trial Details
NCT Number NCT05896137
Lead Sponsor Cascade Pharmaceuticals, Inc
Conditions Primary Sclerosing Cholangitis
Enrollment 50 participants
Start Date 2023-08-07
Primary Completion 2025-11-14 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-13